Among them, specific caspase-1 inhibitors could be evaluated, including VX-765 (belnacasan) for which phase II clinical trials for the treatment of psoriasis have been completed, and VX-740 (pralnacasan) for which phase II clinical trials are in progress for the treatment of rheumatoid arthritis and osteoarthritis (Dhani et al., 2021). Here, CASP1 is linked to rheumatoid arthritis.